American Association for Cancer Research

Skip to Main Content

Table 3.

Three-way sensitivity analysis assuming similar grade distribution between finasteride and placebo arms

Relative risk reduction (%)	Cost of finasteride (U.S. $/mo)	Lifetime prevalence (men diagnosed after the age of 50 years)
Relative risk reduction (%)	Cost of finasteride (U.S. $/mo)			12.5% ($)	30.0% ($)	40.0% ($)	50.0% ($)
25	15	92,413	52,908	39,941	29,883
		30	211,183	117,224	86,141	61,630
		62	467,857	256,218	185,982	130,238
50	15	37,411	19,233	13,299	8,743
		30	91,753	48,435	34,133	22,901
		62	209,191	111,544	79,159	53,498
80	15	20,855	9,024	5,152	2,166
		30	55,864	27,681	18,361	11,019
		62	131,521	68,001	46,907	30,151

Relative risk reduction (%)	Cost of finasteride (U.S. $/mo)	Lifetime prevalence (men diagnosed after the age of 50 years)
Relative risk reduction (%)	Cost of finasteride (U.S. $/mo)			12.5% ($)	30.0% ($)	40.0% ($)	50.0% ($)
25	15	92,413	52,908	39,941	29,883
		30	211,183	117,224	86,141	61,630
		62	467,857	256,218	185,982	130,238
50	15	37,411	19,233	13,299	8,743
		30	91,753	48,435	34,133	22,901
		62	209,191	111,544	79,159	53,498
80	15	20,855	9,024	5,152	2,166
		30	55,864	27,681	18,361	11,019
		62	131,521	68,001	46,907	30,151

NOTE: Results are cost per LYS.